UPDATE: Brean Capital Assumes SCYNEXIS (SCYX) at Buy

October 3, 2016 8:05 AM EDT
Get Alerts SCYX Hot Sheet
Price: $3.72 +3.91%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade SCYX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Updated - October 3, 2016 9:49 AM EDT)

Brean Capital assumed coverage on SCYNEXIS (NASDAQ: SCYX) with a Buy rating and a price target of $16. Analyst Difei Yang is bullish on lead product candidate, SCY-078.

"Throughout the clinical trial process, SCY-078 has showed potent and broad spectrum anti-fungal activity, importantly against echinocandinresistant strains, and a promising safety profile. We expect US and EU launches for IC and IA indications in 2019 and 2020 respectively, as well as a 2020 launch for SCY-078 vs. vulvovaginal candidiasis (VVC). In the interim, investors should look to the FDA meeting, anticipated in 4Q16/1Q17, the initiation of a Phase 3 trial for refractory invasive fungal infections (rIFI) in 4Q16, as well as to the anticipated 1Q17 initiation of the Phase II IC study with top-line data from both expected in 4Q17. We see peak year revenue in the $300 million range with better-than-average success in product development. As such, we assume coverage with a BUY rating and $16 TP."

For an analyst ratings summary and ratings history on SCYNEXIS click here. For more ratings news on SCYNEXIS click here.

Shares of SCYNEXIS closed at $3.87 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Brean Capital

Add Your Comment